Supriya Lifescience (NSE:SUPRIYA) Other Current Liabilities: ₹100 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SUPRIYA Supriya Lifescience Ltd NSE:SUPRIYA
84 GF Score
Price ₹851.00
GF Value ₹812.65
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Supriya Lifescience Other Current Liabilities?

Supriya Lifescience NSE:SUPRIYA -7.79% 84 Other Current Liabilities is ₹100 Mil as of Mar. 2026. GuruFocus rates NSE:SUPRIYA with a GF Score™ of 84/100 and a GF Value™ of ₹812.65 (Fairly Valued). The stock has 8 warning signs investors should review.

Supriya Lifescience's other current liabilities for the quarter that ended in Mar. 2026 was ₹100 Mil.

Supriya Lifescience's quarterly other current liabilities declined from Sep. 2025 (₹62 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹100 Mil).

Supriya Lifescience's annual other current liabilities declined from Mar. 2024 (₹161 Mil) to Mar. 2025 (₹61 Mil) but then increased from Mar. 2025 (₹61 Mil) to Mar. 2026 (₹100 Mil).

Supriya Lifescience Other Current Liabilities Related Terms

Supriya Lifescience Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Supriya Lifescience's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supriya Lifescience Other Current Liabilities Chart

Supriya Lifescience Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
Get a 7-Day Free Trial 278.13 137.52 160.70 61.07 99.51

Supriya Lifescience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.07 0.00 62.19 0.00 99.51
NSE:SUPRIYA
84GF Score
Supriya Lifescience Ltd NSE:SUPRIYA
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supriya Lifescience Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ₹100 Mil mean?
Supriya Lifescience (NSE:SUPRIYA) has a Other Current Liabilities of ₹100 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Supriya Lifescience.
Is Supriya Lifescience's Other Current Liabilities too high?
Supriya Lifescience's current Other Current Liabilities is ₹100 Mil. Overall, Supriya Lifescience has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Supriya Lifescience's Other Current Liabilities compare to VRTX and REGN?
Supriya Lifescience's Other Current Liabilities of ₹100 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Supriya Lifescience. Supriya Lifescience's current Other Current Liabilities is ₹100 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supriya Lifescience stock overvalued right now?
Based on GuruFocus' analysis, Supriya Lifescience (NSE:SUPRIYA) is currently considered Fairly Valued. The stock's GF Value™ is ₹812.65, compared to a current price of ₹851.00 — trading 4.7% above its estimated fair value. The current Other Current Liabilities is ₹100 Mil. Supriya Lifescience's overall GF Score™ is 84/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Supriya Lifescience (NSE:SUPRIYA), the current Other Current Liabilities is ₹100 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supriya Lifescience (NSE:SUPRIYA) Overvalued in 2026?

Based on GuruFocus' analysis, Supriya Lifescience stock appears to be overvalued. The current stock price of ₹851.00 is trading 4.7% above its estimated GF Value™ of ₹812.65. GuruFocus considers Supriya Lifescience to be Fairly Valued.

Key valuation signals for NSE:SUPRIYA:

  • Other Current Liabilities: ₹100 Mil
  • GF Value™: ₹812.65 vs. price of ₹851.00 (4.7% above fair value)
  • GF Score™: 84/100 with 8 warning signs

No single metric tells the full story. See the NSE:SUPRIYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Supriya Lifescience Business Description

Other Exchanges 543434:India
Address Sonawala Road, 207/208, Udyog Bhavan, Goregaon East, Mumbai, MH, IND, 400063
Supriya Lifescience Ltd is a manufacturer of Active Pharmaceutical Ingredients. It is focused on diverse therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatic, and anti-allergic.
84GF Score

Get the complete analysis for NSE:SUPRIYA

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹851.00
Price
₹812.65
GF Value